https://www.selleckchem.com/pr....oducts/elamipretide-
Pre- and post-treatment tumour biopsies for two patients identified temporal genomic heterogeneity, somatic mutations in the gene, which encodes a PI3K-like protein kinase, and emergent somatic mutations related to protein kinase signalling. Copanlisib and trastuzumab can be safely administered with fair overall tolerability. Preliminary evidence of tumour stability was observed in patients with heavily pre-treated, metastatic HER2 positive breast cancer. Several potential biomarkers were identified for further study in the
Beğen
Yorum Yap
Paylaş
